Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function

Brain, Behavior, and Immunity

Volumn 22, Issue 4, 2008, Pages 606-613

  Sacerdote, Paola ^a   Franchi, Silvia ^a   Gerra, Gilberto ^c   Leccese, Vincenzo ^b   Panerai, Alberto E ^a   Somaini, Lorenzo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE DEGLI INFERMI   (Italy)

^c Local Health Unit   (Italy)

Author keywords

Addiction; Buprenorphine; Cytokines; Heroin; Immunosuppression; Methadone; T lymphocytes

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; METHADONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HEROIN DEPENDENCE; HUMANS; IMMUNE SYSTEM; IMMUNOCOMPETENCE; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MALE; METHADONE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41349116718     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2007.12.013     Document Type: Article

References (70)

1. Alonzo N.C., and Bayer B.M. Opioids, immunology and host defence of intravenous drug abusers. Infect. Dis. Clin. North Am. 20 (2002) 317-329
2. Barcellini W., Sacerdote P., Borghi M.O., Rizzardi G.P., Fain C., De Giuli Morghen C., Manfredi B., Lazzarin A., Meroni P.L., Panerai A.E., and Zanussi C. Beta-endorphin content in HIV infected Hut 78 cell line and in peripheral lymphocytes from HIV positive subjects. Peptides 15 (1994) 769-775
3. Beutler B. Innate immunity, an overview. Mol. Immunol. 40 (2004) 845-849
4. Bliesener N., Albrecht S., Schwager A., Wecbecker K., Lichttermann D., and Klingmuller D. Plasma testorene and sexual function in men receiving buprenorphine maintenance for opioid dependence. J. Clin. Endocrinol. Metab. 90 (2005) 203-206
5. Borner C., Stumm R., Hollt V., and Kraus J. Comparative analysis of mu opioid receptor in immune end neuronal cells. J. Neuroimmunol. 1-2 (2007) 56-63
6. Cadet P., Mantione K.J., Zhu W., Kream R.M., Sheehan M., and Stefano G.B. A functionally coupled mu3-opiate receptor/nitric oxide regulatory pathway in human multi-lineage progenitor cells. J. Immunol. 179 (2007) 5839-5844
7. Carrigan K.A., Saurer T.B., Ijames S.G., and Lysle D.T. Buprenorphine produces naltrexone reversible alterations of immune status. Int. Immunopharmacol. 4 (2004) 419-428
8. Charlton B., and Lafferty K.J. The Th1/Th2 balance in autoimmunity. Curr. Op. Immunol. 7 (1994) 793-798
9. D'Elia M., Patenaude J., Hamelin C., Garrel D.R., and Bernier J. No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. Clin. Immunol. 109 (2003) 179-187
10. Derogatis L.R. SCL-90-R: administration, scoring, and procedures: manual 1 (1977), Clin. Psychometric Res., Baltimore, MD
11. Donahoe R.M., and Vlahov D. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J. Neuroimmunol. 83 (1998) 77-87
12. Donahoe R.M. Multiple ways that drug abuse might influence AIDS progression: clues from a monkey model. J. Neuroimmunol. 147 (2004) 28-32
13. Donahoe R.M., Byrd L.D., McClure H.M., Fultz P., Brantley M., Marsteller F., Ansari A.A., Wenzel D., and Aceto M. Consequences of opiate-dependency in a monkey model of AIDS. Adv. Exp. Med. Biol. 373 (1993) 175-181
14. Donahoe R.M., Nicholson J.K.A., Madden J.J., Donahoe F., Shafer D.A., Gordon D., Bokos P., and Falek A. Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E rosette formation and antigenic marker expression. Clin. Immunol. Immunopathol. 41 (1986) 254-264
15. Eisenstein T.K., and Hilburger M.E. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83 (1998) 36-44
16. Falek A., and Hollingsworth F. Opiate and human chromosome alterations. Int. J. Addict. 15 (1980) 155-163
17. Fava M., Guaraldi G.B., Mazzi F., and Rigatelli M. Intervista clinica Strutturata per il DSM-III-R (1993), Organizzazioni Speciali, Florence
18. Fecho K., Maslonek K.A., Dykstra L.A., and Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 276 (1996) 626-636
19. Franchi S., Panerai A.E., and Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus pituitary adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav. Immun. 21 (2007) 767-774
20. Friedman H., Newton C., and Klein T.W. Microbial infections, immunomodulation and drug of abuse. Clin. Microbiol. Rev. 16 (2003) 209-219
21. Gerra G., Ferri M., Polidori E., Santoro G., Zaimovic A., and Sternieri E. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. J. Subst. Abuse Treat 25 (2003) 1-8
22. Gerra G., Borella F., Zaimovicm A., Moim G., Bussandri M., Bubicim C., and Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75 (2004) 37-45
23. Gerra G., Zaimovic A., Raggi M.A., Moi G., Branchi B., Moroni M., and Brambilla F. Experimentally induced aggressiveness in heroin-dependent patients treated with buprenorphine: comparison of patients receiving methadone and healthy subjects. Psychiatry Res. 149 (2007) 201-213
24. Gomez-Flores R., and Weber R. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periacqueductal gray. Immunopharmacology 48 (2000) 145-156
25. Hoebe K., Janssen E., and Beutler B. The interface between innate and adaptive immunity. Nat. Immunol. 5 (2004) 917-974
26. Kapadia F., Vlahov D., Donahoe M.R., and Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin. Inft. Dis. 41 (2005) 1027-1034
27. Kelley K.W., Weigent D.A., and Kooijman R. Protein hormones and immunity. Brain Behav. Immun. 21 (2007) 384-392
28. Kreek M.J. Rational for maintenance pharmacotherapy of opiate dependence. In: O'Brein C.P., and Jaffe J.H. (Eds). Addictive States (1992), Raven Press, Ltd., New York 205-230
29. Kreek M.J. Drug addictions: molecular and cellular endpoints. Ann. NY Acad. Sci. 937 (2001) 27-49
30. Kreek M.J. Long-term pharmacotherapy for opiate addiction: opioid agonists. In: Schuster C.R., and Kuhar M.J. (Eds). Pharmacological Aspects of Drug Dependence 118 (1996), Springer, Berlin Heidelberg, New York 487-492
31. Li H., Liu H., Wang X., Liu X., Guo L., Huang L., Gao L., McNutt M.A., and Li G. The role of transcription factor 1 and YY1 in proximal promoter region in initiation of transcription of the mu opioid receptor gene in human lymphocytes. J. Cell. Biochem. (2007) 10.1002/jcb.21616
32. Madden J.J., Falek A., Shafer D.A., and Glick J.H. Effects of opiates and demographic factors on DNA repair synthesis in human leukocytes. Proc. Natl. Acad. Sci. USA 76 (1979) 5769-5773
33. Madden J.J., Whakey W.L., Ketelsen D., and Donahoe R.M. The morphine-binding site on human activated T-cells is not related to the mu opioid receptor. Drug Alcohol Depend. 1 (2001) 131-139
34. Martucci C., Franchi S., Lattuada D., Panerai A.E., and Sacerdote P. Differential involvement of relb in morphine-induced modulation of chemotaxis NO and cytokine production in murine macrophages and lymphocytes. J. Leukoc. Biol. 81 (2007) 344-354
35. Martucci C., Panerai A.E., and Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 110 (2004) 385-392
36. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., and Rogers T.J. Opioids, opioid receptors and the immune response. Drug Alcohol Depend. 62 (2001) 111-123
37. McLachlan C., Crofts N., Wodak A., and Crowe S. The effects of methadone on immune function among injecting drug users: a review. Addiction 88 (1993) 257-263
38. McDonough R.J., Madden J.J., Falek A., Shafer D.A., Pline M., Gordon D., Bokos P., Kuehnle J.C., and Mendelson J. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes. J. Immunol. 125 (1980) 2539-2543
39. Mosman T.R., and Sad S. The expanding universe of T-cell subsets; Th1, Th2 and more. Immunol. Today 17 (1996) 138-146
40. Neri S., Bruno C.M., Abate G., Ierna D., Mauceri B., Cilio D., Bordonaro F., Pulvirenti D., Italiano C., and Caruso L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin. Ther. 24 (2002) 627-1635
41. Neri S., Bruno C.M., Pulvirenti D., Malaguarnera M., Italiano C., Mauceri B., Abate G., Cilio D., Calvagno S., Tsami A., Interlandi D., Prestianni L., Ricchena M., and Noto R. Randomized clinical trial to compare the effects of metadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 179 (2005) 700-704
42. Neri S., Travali S., Gaetano B., Pulvirenti D., Italiano C., Libbra M., Mauceri B., Abate G., Calcagno S., Cilio D., Aikaterini T., Ignaccolo L., Callari D., and Caruso L. Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine. Hepathology 22 (2007) 74-79
43. Novick D.M., Ochshorn M., Ghali V., Croxson T.S., Mercer W.D., Chiorazzi N., and Kreek M.J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250 (1989) 606-610
44. Pacifici R., Di Carlo S., Bacosi A., Pichini S., and Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int. J. Immunopharmacol. 22 (2000) 603-614
45. Peterson P.K., Molitor T.W., and Chao C.C. Mechanism of morphine-induced immunomodulation. Biochem. Pharmacol. 46 (1993) 343-348
46. Pfohl B., Blum N., Zimmerman M., and Stangl D. Structured Interview for Personality Disorders, revised version (1989), University of Iowa, Iowa City, IA
47. Preston K.L. Buprenorphine for opioid dependence. In: Budd K., and Raffa R. (Eds). Buprenorphine the unique opioid analgesic (2005), Georg Thieme Verlag, Stuttgart
48. Rahim R.T., Meissler J.J., Adler M.W., and Eisenstein T.K. Splenic macrophages and B cells mediate immunosuppression following withdrawal from morphine. J. Leukoc. Biol. 78 (2005) 1185-1191
49. Rahim R.T., Meissler J.J., Cowan A., Rogers T.J., Geller E.B., Gaughan J., Adler M.W., and Eisenstein T.K. Administration of mu-kappa-or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses. Int. Immunopharmacol. 1 (2001) 2001-2009
50. Rahim R.T., Meissler J.J., Zhang L., Rogers T.J., and Eisenstein T.K. Withdrawal from morphine in mice suppresses splenic macrophage function cytokine production and costimulatory molecules. J. Neuroimmunol. 144 (2003) 16-27
51. Rios-Olivares E., Vila M.L., Reyes C.J., Rodriguez J.W., Colon J.H.M., Pagan N.O., Marrero A., Rios-Orraca Z.M., Boukli M.N., Shapshak P., and Robles R.R. Impaired cytokine production and suppresses lymphocyte proliferation activity in HCV-infected cocaine and heroin (speedball users). Drug Alcohol Depend. 85 (2006) 236-243
52. Risdahl J.M., Khanna K.W., Peterson K.W., and Molitor T.W. Opiates and infections. J. Neuroimmunol. 83 (1998) 4-18
53. Romagnani S. Lymphokine production by human T cell in disease states. Annu. Rev. Immunol. 12 (1994) 227-257
54. Roy S., Wang J., Gupta S., Charboneau R., Loh H.H., and Barke R.A. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J. Neuroimmunol. 147 (2004) 78-81
55. Roy S., Wang J., Charboneau R., Loh H.H., and Barke R.A. Morphine induces CD4+ T cell IL-4 expression through an adenyl cyclase mechanism independent of the protein kinase. A pathway 175 (2005) 6361-6367
56. Sacerdote P., Manfredi B., Mantegazza P., and Panerai A.E. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol. 121 (1997) 834-840
57. Sacerdote P., Bianchi M., Gaspani L., Manfredi B., Maucione A., Terno G., and Panerai A.E. Effect of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth. Analg. 90 (2000) 1411-1414
58. Sacerdote P., Manfredi B., Gaspani L., and Panerai A.E. The opioid antagonist naloxone induces a shift from type 1 cytokine pattern to type 2 cytokine pattern in BALB/CJ mice. Blood 95 (2000) 2031-2036
59. Sacerdote P., Limiroli E., and Gaspani L. Experimental evidence for immunomodulatory effect of opioids. In: Machelska H., and Stein C. (Eds). Immune Mechanisms of Pain and Analgesia, Advances in Experimental Medicine and Biology (2001), Kluwer Academic, New York 521 106-112
60. Sacerdote P. Opioids and the Immune system. Palliative Med. 20 (2006) s9-s15
61. Spitzer R.L., Williams J.B.W., Gibbon M., and First M.B. Structured Clinical Interview According to DSM-III-R (1990), American Psychiatric Press, Washington, DC and London, England
62. Sharp B.M. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav. Immun. 20 (2004) 9-14
63. Toribio M.L., Gutierrez-Ramoz J.C., Pezzi L., Marcos M.A.R., and Martinez A.C. Interleukin-2 dependent autocrine proliferation in T-cells development. Nature 342 (1989) 82-85
64. Tubaro E., Avico U., Santiangeli C., Zuccaro P., Cavallo G., Pacifici R., Croce C., and Borelli G. Morphine and methadone impact on human phagocytic physiology. Int. J. Immunopharmacol. 7 (1985) 865-874
65. Ugen K.E., and Nyland S.B. Injecting drugs of abuse and immunity: implication for HIV vaccine testing and efficacy. Springfer Semin. Immun. 28 (2007) 281-287
66. Vallejo R., de Leon-Casasola O., and Benyamin R. Opioid therapy and immunosuppression. Am. J. Therapeut. 11 (2004) 354-365
67. Wang J., Barke R.A., Charboneau R., and Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J. Immunol. 174 (2005) 426-434
68. Wang C.Q., Li Y., Douglas S.D., Wang X., Metzger D.S., Zhang T., and Ho W.Z. Morphine withdrawal enhances hepatitis C virus replicon expression. Am. J. Pathol. 167 (2005) 1333-1340
69. Yeager M.P., Colacchio T.A., Yu C.T., Hildebrandt L., Howell A.L., Weiss J., and Guyre M. Morphine inhibits spontaneous and cytokine enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83 (1996) 500-508
70. Yokota T., Uehara K., and Nomoto Y. Intrathecal morphine suppresses NK activity following abdominal surgery. Can J. Anaesth. 47 (2000) 303-308